



Summary 2nd Quarter FY 2017-18 Medication Monitoring Report Children, Youth and Family System of Care

Of the 64 programs that report on Medication Monitoring, 100% submitted a report.

A total of 1,283 charts were reported open to meds in the quarter.

A total of 72 charts were reviewed (6% of open charts).

13 providers reported no medication distribution during this quarter.


A total of 27 variances were reported (2% of possible variances in reviewed charts).

The variances break out as follows (the number to the right represents programs who answered no and thus had a variance):

varian	ce):	
1	Medication rationale and dosage is consistent with the community standards.	0
2a	Were labs indicated? NOTE: A "NO" answer to this question is not considered a variance. If this question is anwered with "NO", the rest of the questions under 2 (b - f) should be NA	
2b	Were lab results obtained?	3
2c	Were labs reviewed by Medical Staff?	2
2d	Were lab results present in the chart?	2
2e	Were attempts made to obtain appropriate labs?	1
2f	If treatment continues without labs, is there appropriate rationale to continue or discontinue meds?	3
3	Physical health conditions and treatment are considered when prescribing psychiatric medication.	0
4a	No more than 1 of each class concurrently without a clearly documented justification - Stimulants	2
4b	No more than 1 of each class concurrently without a clearly documented justification - Mood Stabilizers	2
4c	No more than 1 of each class concurrently without a clearly documented justification - Antidepressants	2
4d	No more than 1 of each class concurrently without a clearly documented justification - Antipsychotics	2
4e	No more than 1 of each class concurrently without a clearly documented justification - Antiparkinsonian	2
4f	No more than 1 of each class concurrently without a cl4early documented justification - Hypnotics	0
5	Were Adverse Drug Reactions and/or Side Effects treated and managed effectively?	0
6	Was informed consent obtained, as evidenced by a signed consent form or ex-parte order?	1
7	Was the diagnosis in concordance with prescribed medication?	0
8a	Did treating M.D. document client's response to medication therapy?	1
8b	Did treating M.D. document the presence/absence of side effects?	1
8c	Did treating M.D. document the extent of client's compliance with the prescribed medication regime and relevant interventions?	1
9a-1	Age 12 – 17 - Less than 4 psychotropic medications (allows no more than 3) - Does the number of medications prescribed meet the standards?	1
9b-1	Age 6 – 11 – Less than3 psychotropic medications (allows no more than 2) - Does the number of medications prescribed meet the standards?	1
9c-1	Age 0 – 5 - Less than 2 psychotropic medications (allows 1) - CA Guidelines allows for stimulant, Atomoxetine, Guanfacine, Clonidine or Risperidone (Risperidone for Autistic Spectrum disorders and associated aggression only). Does the prescribing meet the Guideline recommendation?	0
9c-2	Does the number of medications prescribed meet the standards?	0

Data Sources: Medication Monitoring Reports Q2, FY 17-18

Report By: County of San Diego HHSA BHS QI - Quality Management Team - TW



Type of Variance	1	2b	2c	2d	2e	2f	3	4a	4b	4c	4d	4e	4f	5	6	7	8a	8b	8c	9a-1	9b-1	9c-1	9c-2	al Vari	Tot al Cha
First Quarter.	0	4	2	3	1	1	1	2	2	2	2	2	0	0	1	1	0	2	0	1	0	0	0	27	71
Second Quarter	0	3	2	2	1	3	0	2	2	2	2	2	0	0	1	0	1	1	1	1	1	0	0	27	72
Third Quarter																									
Fourth Quarter																									
Totals	0	3	4	5	2	4	1	4	4	4	4	4	0	0	2	1	1	3	1	2	1	0	0	54	143

IANCE QUESTION

- 1. Medication rationale and dosage is consistent with the community standards.
- 2a. Were labs indicated? (a no answer does not constitute a variance)
- 2b. Were lab results obtained?
- 2c. Were labs reviewed by Medical Staff?
- 2d. Were lab results present in the chart?
- 2e. Were attempts made to obtain appropriate labs?
- 2f. If treatment continues without labs, is there appropriate rationale to continue or discontinue meds?
- Physical health conditions and treatment are considered when prescribing psychiatric medication.
- 4a. No more than 1 of each class concurrently without a clearly documented justification Stimulants
- 4b. No more than 1 of each class concurrently without a clearly documented justification Mood Stabilizers
- 4c. No more than 1 of each class concurrently without a clearly documented justification Antidepressants
- 4d. No more than 1 of each class concurrently without a clearly documented justification Antipschotics
- 4e. No more than 1 of each class concurrently without a clearly documented justification Antiparkinsonian


- 4f. No more than 1 of each class concurrently without a clearly documented justification Hypnotics (including Trazodone, Diphenhydramine, Zolpidem, Melatonin, Benzodiazepines. Not including Clonidine, Guanfacine & Prazosin)
- 5. Were Adverse Drug Reactions and/or Side Effects treated and managed effectively?
- 6. Was informed consent obtained, as evidenced by a signed consent form or ex-parte order?
- 7. Was the diagnosis in concordance with prescribed medication?
- 8a. Did treating M.D. document client's response to medication therapy?
- 8b. Did treating M.D. document the presence/absence of side effects?
- 8c. Did treating M.D. document the extent of client's compliance with the prescribed medication regime and relevant interventions?
- 8d. Did treating M.D. document measures taken to educate client/parent in regard to medication management?
- 9a-1. Age 12 17 Less than 4 psychotropic medications (allows no more than 3) Does the number of medications prescribed meet the standards?
- 9b-1. Age 6 11 Less than 3 psychotropic medications (allows no more than 2) Does the number of medications prescribed meet the standards?
- 9c.1. Age 0 5 Less than 2 psychotropic medications (allows 1). Guidelines allow for stimulant, Atomoxetine, Guanfacine, Clonidine or Risperidone (Risperidone for Autistic Spectrum disorders and associated 9c-2. Age 0 5 Less than 2 psychotropic medications (allows 1). Does the number of medications prescribed meet the standards?

CYF MENTAL HEALTH SERVICES PROVIDER MEDICATION MONITORING

Compliance Analysis - Variances 2 (Labs) and 6 (Informed Consent)

	Charts Reviewed	# Variances								
		2b	2c	2d	2e	2f	6			
1st Quarter	71	4	2	3	1	1	1			
2nd Quarter	72	3	2	2	1	3	1			
3rd Quarter										
4th Quarter										

	Compliance Rate												
2b	2c	2d	2e	2f	6								
94%	97%	96%	99%	99%	99%								
96%	97%	97%	99%	96%	99%								




2a. Were Labs indicated? NOTE: A negative response to this question is not considered a variance.

- 2b. Were lab results obtained
- 2c. Were labs reviewed by Medical Staff
- 2d. Were lab results present in chart
- 2e. Were attempts made to obtain appropriate labs
- 2f. If treatment continues without labs, is there appropriate rationale to continue or discontinue meds
- 6. Informed consent is evidenced by a signed consent form


CYF MENTAL HEALTH SERVICES PROVIDERS MEDICATION MONITORING

Compliance Analysis (Variance 2 - Labs and Variance 6 - Informed Consent)

By Region						
	2b	2c	2d	2e	2f	6
Central	0	0	0	0	2	0
East	0	0	0	0	0	0
North Central	0	2	0	0	0	1
North Coastal	0	0	0	0	0	0
North Inland	1	0	1	0	1	0
South	2	0	1	1	0	0
Total - Variance 2	11			Total - V	ariance 6	1



By Level of Care						
	2b	2c	2d	2e	2f	6
Day Treatment	0	1	0	0	0	1
Outpatient	3	1	2	1	3	0
Case Management	0	0	0	0	0	0
Residential Patch	0	0	0	0	0	0
Total - Variance 2	11			Total - Variance 6		1



Note: The numbers reported here represent the instances of non-compliance as reported by the providers.